Follicle-stimulating hormone

Wistar Scientists Engineer New NK cell Engaging Immunotherapy Approaches to Target and potentially Treat recalcitrant Ovarian Cancer

Retrieved on: 
Wednesday, November 1, 2023

Ovarian cancer demonstrates a low response rate to standard-of-care treatments like chemotherapies, PARP inhibitors and the widely used checkpoint inhibitor, PD-1.

Key Points: 
  • Ovarian cancer demonstrates a low response rate to standard-of-care treatments like chemotherapies, PARP inhibitors and the widely used checkpoint inhibitor, PD-1.
  • In the small proportion of ovarian cancer patients that do respond to these treatments, resistance becomes problematic over time — resulting in tumor escape and cancer progression.
  • NK cells have been recently described to express Siglec-7, so the team tested two new strategies to engage and activate NK cells against ovarian cancer through Siglec-7.
  • Wistar scientists are focused on solving some of the world’s most challenging and important problems in the field of cancer, infectious disease, and immunology.

Antev Receives US FDA Guidance on Teverelix® Phase 3 Trial Design for Treating Advanced Prostate Cancer Patients with Increased Cardiovascular Risk

Retrieved on: 
Wednesday, March 8, 2023

Up to 30% of advanced prostate cancer patients on Androgen Deprivation Therapy have pre-existing Cardiovascular Disease.

Key Points: 
  • Up to 30% of advanced prostate cancer patients on Androgen Deprivation Therapy have pre-existing Cardiovascular Disease.
  • This would be the first Phase 3 trial for a specific label to treat prostate cancer in patients with increased cardiovascular risk, addressing a significant need for prostate cancer drugs with a better cardiac toxicity profile.
  • Teverelix, a decapeptide, has the potential to be the first hormone therapy specifically approved to treat advanced prostate cancer patients with a history of cardiovascular disease.
  • “We are delighted to reach this critical milestone in Antev’s journey to secure regulatory guidance to develop Teverelix in advanced prostate cancer patients with increased cardiovascular risk,” commented Amit Kohli, Chief Executive Officer of Antev.

Natalist Introduces New Products to Support Every Stage of the Reproductive Journey

Retrieved on: 
Thursday, June 23, 2022

AUSTIN, Texas, June 23, 2022 /PRNewswire/ -- Natalist, a women's health company founded and led by moms that offers consumers fertility, pregnancy, and postpartum essentials that are 100% plastic neutral, announced today the launch of four new products, including CoQ10 Gummies, Prenatal Gummies, Pregnancy Test Strips, and an at-home collection Women's Fertility Test. These products are now available at Natalist.com and retailers nationwide as the brand rapidly expands to bring high-quality, doctor-recommended products and resources to people at every stage of their reproductive journeys.

Key Points: 
  • These products are now available at Natalist.com and retailers nationwide as the brand rapidly expands to bring high-quality, doctor-recommended products and resources to people at every stage of their reproductive journeys.
  • "Natalist is here to change that with fertility, pregnancy, and postpartum products designed by moms and doctors to support every step of your reproductive journey."
  • Natalist is uniquely positioned to serve women and families on their path to parenthood with its comprehensive and affordable products.
  • Natalist takes the guesswork out of reproductive health with thoughtfully designed products that empower consumers to support every step of their fertility health and reproductive journeys.

Global IVF Services Market (2022 to 2031) - Featuring Betamedics, CHA Fertility Center and Morpheus IVF Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, March 7, 2022

The IVF services market consists of sales of in-vitro fertilization (IVF) services by entities (organizations, sole traders and partnerships) that provide these services.

Key Points: 
  • The IVF services market consists of sales of in-vitro fertilization (IVF) services by entities (organizations, sole traders and partnerships) that provide these services.
  • The main types of cycles in IVF services markets are fresh IVF cycles (non-donor), thawed IVF cycles (non-donor) and donor egg IVF cycles.
  • The high cost of IVF services limits the in-vitro fertilization (IVF) services market.
  • The high cost of IVF services makes it unavailable to low- and middle-income populations negatively affecting the IVF services' market growth.

Global IVF Services Market (2021 to 2030) - Players Include Bangkok IVF Center, Fertility Associates and Morpheus IVF Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 11, 2021

The IVF services market consists of sales of in-vitro fertilization (IVF) services by entities (organizations, sole traders and partnerships) that provide these services.

Key Points: 
  • The IVF services market consists of sales of in-vitro fertilization (IVF) services by entities (organizations, sole traders and partnerships) that provide these services.
  • The rising infertility rate made people resort to IVF services contributing to the growth of the market.
  • The high cost of IVF services limits the in-vitro fertilization (IVF) services market.
  • The high cost of IVF services makes it unavailable to low- and middle-income populations, negatively affecting the IVF services' market growth.

Anixa Biosciences Announces First Chinese Patent on its CAR-T Cancer Therapy Technology

Retrieved on: 
Wednesday, October 6, 2021

The patent is titled, "Methods and Compositions for Treating Cancer," and the inventors are Drs.

Key Points: 
  • The patent is titled, "Methods and Compositions for Treating Cancer," and the inventors are Drs.
  • Dr. Conejo-Garcia is Chair of the Department of Immunology at Moffitt Cancer Center and Dr. Perales-Puchalt is Vice President of R&D at Geneos Therapeutics.
  • The patent is assigned to The Wistar Institute and Anixa Biosciences' majority-owned subsidiary, Certainty Therapeutics, Inc. is the exclusive, world-wide licensee.
  • The therapy based on this technology was recently authorized by the U.S. Food and Drug Administration (FDA) for Phase 1 clinical testing.

Clarus Therapeutics Announces Comprehensive Settlement of Patent Litigation With Lipocine

Retrieved on: 
Thursday, July 15, 2021

These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range.

Key Points: 
  • These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range.
  • Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation.
  • Safety and efficacy of JATENZO in males less than 18 years old have not been established.
  • Before initiating JATENZO, consider the patient's baseline cardiovascular risk and ensure blood pressure is adequately controlled.

First Stop Health Grew Revenue 59% in 2020, Connected Telemedicine Members With Doctors in Under 3 Minutes Throughout Pandemic

Retrieved on: 
Thursday, February 4, 2021

During the same period, FSHSM Telemedicine demand increased 93% and the companyscaled to meet the increased needs of patients through its Care IgniteSM platform.

Key Points: 
  • During the same period, FSHSM Telemedicine demand increased 93% and the companyscaled to meet the increased needs of patients through its Care IgniteSM platform.
  • Wait times for FSH patients averaged under seven minutes for this period, and quickly returned to pre-pandemic wait times of under three minutes.
  • Keeping patient satisfaction at the center of all telemedicine visits in 2020 earned FSH a Net Promoter Score (NPS) of 77 from patients.
  • Our Telemedicine and Virtual Mental Health services are available as an employee benefit from employersand to students/staff at higher education institutions.

Follicle Stimulating Hormone Market to be Driven by Rising Cases of Infertility in Men and Women, Industry Forecast to 2026: Radiant Insights, Inc.

Retrieved on: 
Wednesday, July 15, 2020

Follicle stimulating hormone (FSH) and luteinizing hormone (LH) is responsible for production of healthy eggs in men and women.

Key Points: 
  • Follicle stimulating hormone (FSH) and luteinizing hormone (LH) is responsible for production of healthy eggs in men and women.
  • The follicle stimulating hormone market is driven by the rising cases of infertility in men and women, rise in disposable income of population and extensive availability of qualified physicians.
  • By product, the follicle stimulating hormone market can be segmented as urinary follicle stimulating hormone and recombinant follicle stimulating hormone.
  • The Follicle Stimulating Hormone industry is not concentrated, these manufacturers range from large multinational corporations to small privately owned companies compete in this industry.

Follicle Stimulating Hormone Market to be Driven by Rising Cases of Infertility in Men and Women, Industry Forecast to 2026: Radiant Insights, Inc.

Retrieved on: 
Wednesday, July 15, 2020

Follicle stimulating hormone (FSH) and luteinizing hormone (LH) is responsible for production of healthy eggs in men and women.

Key Points: 
  • Follicle stimulating hormone (FSH) and luteinizing hormone (LH) is responsible for production of healthy eggs in men and women.
  • The follicle stimulating hormone market is driven by the rising cases of infertility in men and women, rise in disposable income of population and extensive availability of qualified physicians.
  • By product, the follicle stimulating hormone market can be segmented as urinary follicle stimulating hormone and recombinant follicle stimulating hormone.
  • The Follicle Stimulating Hormone industry is not concentrated, these manufacturers range from large multinational corporations to small privately owned companies compete in this industry.